KIMERA COVID-19 FDA IND FILING

In an effort to mitigate the effects of the current global pandemic and in compliance with the FDA’s mandate of requiring exosome manufacturers to file an investigational new drug (IND) application for regenerative medicine products, Kimera Labs has filed an IND for the treatment of symptoms associated with COVID-19 in an attempt to shorten disease duration as well as suppress hospital admissions. We are currently in process with the FDA as to administration frequency prior to the initiation of patient dosing.